Showing results (801-810 of 3,350) with videos related to

Sort By:
Pageof 335
Pharmacoeconomics|September 5, 2026
Bayesian Dynamic Borrowing to Enhance Evidence for New TherapiesSean Yiu, Katya Galactionova, Steven Yuen, et al.
Pharmacoeconomics|July 23, 2026
Uncertainty in Economic Evaluation: A Pragmatic Guide for Health Technology Assessment (HTA) Agencies in Resource-Constrained SettingsSiobhan Botwright, Syarifah Liza Munira, Itamar Megiddo, et al.
Pharmacoeconomics|October 9, 2026
Waiting for Trial Evidence or Using Real-World Evidence: Trade-Offs for Coverage with Evidence DevelopmentBoshen Jiao, Yizhi Liang, Liyuan Tao, et al.
Pharmacoeconomics|October 23, 2026
Beyond Traditional Cost-Effectiveness Analysis: Operationalizing the Equivalent Income Approach for Equity-Sensitive Health Technology AssessmentPauline Chauvin, Clémence Thébaut
Pharmacoeconomics|December 14, 2022
Caregiver Burden of Spinal Muscular Atrophy: A Systematic ReviewErik Landfeldt, Sophia Abner, Astrid Pechmann, et al.
Pharmacoeconomics|May 8, 2022
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung CancerWoojung Lee, William B Wong, Stacey Kowal, et al.
Pharmacoeconomics|October 22, 2020
Correction to: Perspective and Costing in Cost‑Effectiveness Analysis, 1974-2018David D Kim, Madison C Silver, Natalia Kunst, et al.
Pharmacoeconomics|August 29, 2020
Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity ApproachJessica Ochalek, Haiyin Wang, Yuanyuan Gu, et al.
Pharmacoeconomics|May 27, 2021
A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy PopulationEmily McDool, Clara Mukuria, John Brazier
Pharmacoeconomics|December 18, 2020
Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology AssessmentSeamus Kent, Edward Burn, Dalia Dawoud, et al.
Pageof 335